Evidence map›Paper›PMID 37486819›Full record

ArticleHealthcare policy = Politiques de sante2023

Commentary: Access to Psychedelics for Psychological Suffering at the End of Life - Prioritizing Our Priorities.

Daniel Rosenbaum, Sarah Hales, Daniel Z Buchman

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Healthcare policy = Politiques de sante, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care.Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association · 2025
    Article
  4. A Problem of Money and Health: The Need for Value in Healthcare.Healthcare policy = Politiques de sante · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Daniel RosenbaumPsychiatrist and Clinician Investigator, Nikean Psychedelic Psychotherapy Research Centre, University Health Network, Lecturer, Department of Psychiatry, University of Toronto, Toronto, ON.
Sarah HalesPsychiatrist and Clinician Investigator, Department of Supportive Care and Centre for Mental Health, University Health Network, Assistant Professor, Department of Psychiatry, University of Toronto, Toronto, ON.
Daniel Z BuchmanBioethicist and Independent Scientist, Centre for Addiction and Mental Health, Assistant Professor, Dalla Lana School of Public Health, University of Toronto, Toronto, ON.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We agree with Kratina et al. (2023) that the problem of psychological suffering at the end of life deserves attention from a policy standpoint and that psychedelic therapies show promise in this clinical context. However, we argue the following in this rejoinder: (1) disproportionate attention to psychedelics may overstate the current evidence base, potentially diverting resources away from existing evidence-based programs; (2) a more pressing policy priority related to this public health problem is to address population-level inequities in accessing high-quality, early and holistic palliative care, including psychosocial care; and (3) discussions about expanded access to psychedelics must also foreground equity issues.

Indexed as

HallucinogensDeathHumansPalliative CareHallucinogens

Identifiers

PMID37486819
PMCPMC10370398

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.